welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- login
Capricor receives rare pediatric disease designation for DMD drug
The U.S. Food and Drug Administration (FDA) has granted a Rare Pediatric Disease Designation to CAP-1002 to treat Duchenne muscular dystrophy (DMD).
If approved, CAP-1002 manufacturer, Capricor Therapeutics would receive a Priority Review Voucher which can be worth millions of dollars.
DMD is a rare genetic disorder that results in progressive degeneration and muscle due to disruption of the dystrophin protein complex in muscle tissue. DMD patients typically lose the ability to walk between the ages of 10 to 12 and typically die in their 20’s of heart failure. There approximately 15,000 to 20,000 affected people in the U.S
rareRelated
-
Capricor Receives Rare Pediatric Disease Designation from FDA for CAP-1002 for Patients with Duchenne Muscular Dystr...Capricor Therapeutics, Inc., a biotechno...
-
Capricor trial failure in heart disease might offer another opportunityOn Friday Capricor Therapeutics announce...
-
HOPE-Duchenne (Halt cardiomyOPathy progrEssion in Duchenne)Male subjects with cardiomyopathy second...
-
Capricor to Meet with FDA under its RMAT Designation to Discuss HOPE-2 Clinical TrialCapricor Therapeutics announced today th...
-
A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy (HOPE-2)HOPE-2 is a double-blind clinical trial ...
-
FibroGen Receives Fast Track Designation From the U.S. FDA for Pamrevlumab for the Treatment of Idiopathic Pulmonary...FibroGen, Inc., a biopharmaceutical comp...
-
Archived drug prevents Duchenne muscular dystrophy muscle loss in miceA drug that showed promise in clinical t...